Page 2 of 5 · 111 questions tagged cardiovascular.
The particulars: SOUL · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
I have three data points across nine months, which I hope is enough to see a trend. I can do the algebra. I am not confident about the conversion factors. If there is…
This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I want the working, not the result — I need to be able to…
The case in front of me: REDEFINE-1 · tirzepatide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
The case in front of me: SUSTAIN-6 · oral semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if…
I am reading the trial table rather than the press release, which is why the numbers differ. I want to understand what this actually establishes, as opposed to what…
Concretely: STEP 4 · tirzepatide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…
Details up front: ATTAIN-1 · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
What I have: STEP 3 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
The particulars: PIONEER-4 · survodutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
I have the full paper rather than the abstract, and the supplementary appendix. I would rather understand the derivation than memorise the outcome. Two people I asked…
Stated plainly: TRIUMPH-3 · mazdutide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…
For reference: FLOW · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
I have the full paper rather than the abstract, and the supplementary appendix. I can do the algebra. I am not confident about the conversion factors. If there is a…
The particulars: SUSTAIN-6 · semaglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
What I am working with: SELECT · mazdutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…
Concretely: PIONEER-1 · tirzepatide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
I have three numbers on my report that all claim to measure roughly the same risk and they do not agree about how I am doing. LDL-C 2.6 mmol/L, which is described in…
I have three data points across nine months, which I hope is enough to see a trend. I would rather understand the derivation than memorise the outcome. Two people I…
The particulars: PIONEER-4 · semaglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
The specifics, since they change the answer: REDEFINE-1 · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to…
I have the full paper rather than the abstract, and the supplementary appendix. I would rather understand the derivation than memorise the outcome. Two people I asked…
I have the full paper rather than the abstract, and the supplementary appendix. I would rather understand the derivation than memorise the outcome. Two people I asked…
What I am working with: PIONEER-1 · mazdutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…